PURE Bioscience, Inc. (PURE)
OTCMKTS · Delayed Price · Currency is USD
0.0560
+0.0040 (7.69%)
At close: Feb 18, 2026

PURE Bioscience Income Statement

Millions USD. Fiscal year is Aug - Jul.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Oct '25 Jul '25 Jul '24 Jul '23 Jul '22 Jul '21
2.352.21.961.881.853.93
Revenue Growth (YoY)
31.00%12.17%4.58%1.29%-52.81%-43.23%
Cost of Revenue
0.930.90.810.910.851.85
Gross Profit
1.431.31.150.9712.08
Selling, General & Admin
3.123.263.984.34.054.05
Research & Development
0.330.320.30.30.320.34
Operating Expenses
3.453.584.284.64.374.39
Operating Income
-2.02-2.27-3.13-3.63-3.37-2.31
Interest Expense
-0.33-0.3-0.16-0.01-0.01-0
Other Non Operating Income (Expenses)
0.180.17-0-0--0
EBT Excluding Unusual Items
-2.17-2.4-3.29-3.65-3.38-2.32
Asset Writedown
---0.06-0.32-0.35-
Other Unusual Items
----0.24-
Pretax Income
-2.17-2.4-3.35-3.96-3.49-2.32
Net Income
-2.17-2.4-3.35-3.96-3.49-2.32
Net Income to Common
-2.17-2.4-3.35-3.96-3.49-2.32
Shares Outstanding (Basic)
1121121121118987
Shares Outstanding (Diluted)
1121121121118987
Shares Change (YoY)
0.01%0.01%0.41%25.41%1.91%3.03%
EPS (Basic)
-0.02-0.02-0.03-0.04-0.04-0.03
EPS (Diluted)
-0.02-0.02-0.03-0.04-0.04-0.03
Free Cash Flow
-1.76-2.02-2.53-3.31-2.5-1.69
Free Cash Flow Per Share
-0.02-0.02-0.02-0.03-0.03-0.02
Gross Margin
60.66%59.17%58.69%51.73%53.97%52.84%
Operating Margin
-85.98%-103.18%-159.50%-193.29%-181.87%-58.85%
Profit Margin
-92.35%-108.95%-170.66%-211.03%-188.40%-59.05%
Free Cash Flow Margin
-74.85%-91.51%-128.94%-176.40%-134.86%-42.98%
EBITDA
-2.06-2.27-2.98-3.51-3.16-2.14
EBITDA Margin
-87.43%-103.09%-151.96%-187.05%-170.37%-54.47%
D&A For EBITDA
-0.0300.150.120.210.17
EBIT
-2.02-2.27-3.13-3.63-3.37-2.31
EBIT Margin
-85.98%-103.18%-159.50%-193.29%-181.87%-58.85%
Revenue as Reported
2.352.21.961.881.853.93
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.